Andrea Tomisser

The rationale and study design of two phase II trials examining the effects of BI 685509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis

J. Ertle, J. Trebicka, A. Berzigotti, 2023, Trials.